Impact of Oral Antipsychotic Medication Adherence on Healthcare Resource Utilization Among Schizophrenia Patients with Medicare Coverage
Nonadherence to antipsychotic medications is widespread and compromises the outcome of patients with schizophrenia. Using the MarketScan Medicare claims database, this study examined the impact of medication adherence on healthcare utilization among Medicare insured schizophrenia patients. The study population was separated into two cohorts defined by medication adherence, one with a medication possession ratio (MPR) ≥0.7 (high adherence) and the other with a MPR <0.7(low adherence). Of the 354 patients identified, 126 (36 %) had high adherence (mean ± SD MPR 0.94 ± 0.09) and 228 (64 %) had low adherence (MPR 0.24 ± 0.19). All cause hospitalizations (0.68 vs. 0.44; p = 0.015) and length of stay (LOS) (7.0 vs. 2.6 days; p = 0.005), and relapse hospitalizations (0.22 vs. 0.11; p = 0.028) and LOS (3.2 vs. 0.7 days; p = 0.027) were greater among patients with low adherence. Low adherent Medicare insured patients with schizophrenia require significantly more inpatient care and represent a patient population in which effective interventions are needed to improve disease management.
KeywordsSchizophrenia Adherence Healthcare utilization Costs
This research and development of this manuscript was supported by Otsuka America Pharmaceutical, Inc. and H. Lundbeck A/S.
Conflict of interest
Steve Offord and Dario Mirski are employees of Otsuka America Pharmaceutical, Inc. Jay Lin is an employee of Novosys Health, which has received research funds from Otsuka America Pharmaceutical, Inc. in connection with conducting this study and development of this manuscript. Bruce Wong is a paid consultant for Otsuka America Pharmaceutical, Inc. in connection with conducting this study and development of this manuscript. Ross Baker is an employee of Otsuka Pharmaceutical Development and Commercialization, Inc.
- Kelin, K., Lambert, T., Brnabic, A. J., Newton, R., Ye, W., Escamilla, R. I., et al. (2011). Treatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherence. Patient Preference and Adherence, 5, 213–222.PubMedCrossRefGoogle Scholar
- Lindenmayer, J.-P., Liu-Seifert, H., Kulkarni, P. M., Kinon, B. J., Stauffer, V., Edwards, S. E., et al. (2009). Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. The Journal of Clinical Psychiatry, 70(7), 990–996.PubMedCrossRefGoogle Scholar
- Meesters, P. D., de Haan, L., Comijs, H. C., Stek, M. L., Smeets-Janssen, M. M. J., Weeda, M. R., et al. (2012). Schizophrenia spectrum disorders in later life: Prevalence and distribution of age at onset and sex in a dutch catchment area. The American Journal of Geriatric Psychiatry, 20(1), 18–28.PubMedCrossRefGoogle Scholar
- Stephenson, J. J., Tuncelli, O., Gu, T., Eisenberg, D., Panish, J., Crivera, C., et al. (2012). Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians’ perceptions of adherence vs. pharmacy claims. International Journal of Clinical Practice, 66(6), 565–573.PubMedCrossRefGoogle Scholar
- US Census Bureau. (2011). US census bureau newsroom: 2010 Census: 2010 census shows 65 and older population growing faster than total U.S. population. Retrieved from http://www.census.gov/newsroom/releases/archives/2010_census/cb11-cn192.html.